Venturis Therapeutics, Inc. announces applications for four patents related to the use of therapeutic angiogenesis in the treatment of diseases related to the COVID-19 virus, as well as diseases related to other viruses

Publisher: The Insight Partners

Venturis Therapeutics, Inc. ("VT") announced today that it has applied for four provisional patents relating to the treatment and / or prevention of virus-induced diseases related to the COVID- 19, as well as other viruses. These new patent applications include the following general areas: cardiac injury and virus-induced stroke; severe acute respiratory syndrome (SARS ); intestinal dysfunction or damage to intestinal epithelial cells; and renal dysfunction or failure.

In the last few months, the VT team has been reviewing numerous reports and initial data from doctors around the world, concerning diseases related to lesions of epithelial cells and microvascular tissue, caused by the virus of COVID-19. Lesions are recorded in patients of different age groups, during and after the apparent recovery from the COVID-19 virus and in patients who have experienced severe or only mild symptoms of the virus. The presentation of virus-induced diseases can include, without limitation, strokes, organ failure, fibrosis, sudden blood clots and ischemia of cells and tissues. VT has many years of experience in the use of therapeutic angiogenesis in the treatment and regeneration of ischemic and / or injured epithelial cells and microvascular tissues.

VT hopes that these new patents, combined with other VT patents, such as its current stroke-related patents, will allow VT to expand the development of current and discovered methods and therapies to treat potentially fatal diseases and distressing, in large patient populations. With these proposed and existing patents, VT seeks to position itself at the forefront of private sector companies, which are combating the devastating effects of these diseases.